Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine

Canadian Veterinary Journal

Volumn 49, Issue 4, 2008, Pages 379-385

  Araujo, Joseph A ^a,b   Landsberg, Gary M ^b,c   Milgram, Norton W ^a,b,d   Miolo, Alda ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b CanCog Technologies Incorporated   (Canada)

^c North Toronto Animal Clinic   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Innovet Italia Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PHOSPHATIDYLSERINE; PLANT EXTRACT; PYRIDOXINE; VITAMIN B COMPLEX;

AGING; ANIMAL; ARTICLE; CHEMISTRY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOG; DRUG EFFECT; FEMALE; GINKGO BILOBA; MALE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; RANDOMIZATION; SAFETY; SHORT TERM MEMORY; TREATMENT OUTCOME;

AGING; ANIMALS; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOGS; FEMALE; GINKGO BILOBA; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; PHOSPHATIDYLSERINES; PLANT EXTRACTS; PYRIDOXINE; RANDOM ALLOCATION; SAFETY; TREATMENT OUTCOME; VITAMIN B COMPLEX; VITAMIN E;

CANIS FAMILIARIS; GINKGO BILOBA;

EID: 42649127765     PISSN: 00085286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 2000;21: 89-96.
2. Rofina J, van Andel I, van Ederen AM, van Asten AJAM, Wilhelm J, Gruys E. Canine counterpart of senile dementia of the Alzheimer type: amyloid plaques near capillaries but lack of spatial relationship with activated microglia and macrophages. Amyloid 2003;10:86-96.
3. Nielson JC, Hart BL, Cliff KD, Ruehl WW. Prevalence of behavioral changes associated with age-related cognitive cognitive impairment in dogs. J Am Vet Med Assoc 2001;218:1787-1791.
4. Hills Pet Nutrition, U.S. Marketing Research Summary, Omnibus Study on Aging Pets, Nov. 2000.
5. Osella MC, Re G, Odore R, et al. Canine cognitive dysfunction syndrome; Prevalence, clinical signs and treatment with a neuroprotective nutraceutical. Appl Anim Behav Sci 2007;105:297-310.
6. Adams B, Chan A, Callahan H, Milgram NW. The canine as a model of human cognitive aging: recent developments. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:675-692.
7. Studzinski CM, Christie LA, Araujo JA, et al. Visuospatial function in the beagle dog: An early marker of cognitive decline in a model of human cognitive aging and dementia. Neurobiol Learn Mem 2006;86: 197-204.
8. Landsberg G, Hunthausen W, Ackerman L. Handbook of Behavior Problems of the Dog and Cat. 2nd ed. Edinburgh: Saunders, 2003: 269-322.
9. Landsberg G, Ruehl W. Geriatric behavioral problems. Vet Clinics North Am Small Anim Pract 1997;27:1537-1559.
10. Borras D, Ferrer I, Pumarola M. Age related changes in the brain of the dog. Vet Pathol 1999;36:202-211.
11. Cummings BJ, Satou T, Head E, et al. Diffuse plaques contain c-terminal AB42 and not AB40: Evidence from cats and dogs. Neurobiol Aging 1996;17:653-659.
12. Head E, Liu J, Hagen TM, et al. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 2002;82: 375-381.
13. Rofina JE, Singh K, Skolumalova-Vesela A, et al. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid: J Protein Folding Disord 2004; 11:90-100.
14. Tapp PD, Siwak CT, Gao FQ, et al. Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. J Neurosci 2004; 24:8205-8213.
15. Cummings BJ, Head E, Afagh AJ, Ivy GO, Milgram NW, Cotman CW. β-Amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 1996;66:11-23.
16. Colle MA, Hauw JJ, Crespeau F, et al. Vascular and parenchymal Aβ deposition in the aging dog : Correlation with behaviour. Neurobiol Aging 2000;21:695-704.
17. Araujo JA, Chan AD, Winka LL, Seymour PA, Milgram NW. Dose-specific effects of scopolamine on canine cognition: Impairment of visu-ospatial memory, but not visuospatial discrimination. Pyschopharmacology 2004;175:92-98.
18. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Psychopharmacol Biol Psychiatry 2005;29:411-422.
19. Adams SM, Standridge JB. What should we eat? Evidence from observational studies. South Med J 2006;99:744-748.
20. Kidd PM. Neurodegeneration from mitochondrial insufficiency; nutrients stem cells, growth factors, and prospects for brain rebuilding through integrative management. Altern Med Rev 2005;10:268-293.
21. Donini LM, De Felice MR, Cannella C. Nutritional status determinants and cognition in the elderly. Arch Gerentol Geriatr 2007;44: 143-153.
22. Araujo JA, Studzinski CM, Head E, Cotman CW, Milgram NW. Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging. AGE 2005;27: 27-37.
23. Milgram NW, Zicker SC, Head EA, et al. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 2002;23:737-745.
24. Cena F, Colangeli R, Fassola F, et al. Effect of a combination of phosphatidylserine, Ginkgo biloba, vitamin E and pyridoxine on clinical signs of brain ageing; a pilot multicentric study. Proc 2nd Annu Meet Eur Coll Vet Behav Med Companion Anim & 11th Annu Meet Eur Soc Vet Clin Ethology 2005:127-135.
25. Colangeli R, Antoni M, Cena F, et al. [The effect and tolerability of a neuroprotective nutraceutical containing phosphatidylserine and Ginkgo biloba on clinical signs of brain aging in dogs. A pilot multicenter study.] Veterinaria 2005;19:13-18. Italian.
26. Heath SE, Barabas S, Craze PG. Nutritional supplementation in cases of canine cognitive dysfunction - a clinical trial. Appl Anim Behav Sci 2007;105:274-283.
27. Canadian Council on Animal Care. Guide to the Care and Use of Experimental Animals, vols. 1 and 2. Ottawa: Canadian Council on Animal Care, 1993.
28. Landsberg G, Araujo JA. Behavior problems in geriatric pets. Vet Clinics North Am Small Anim Pract 2005;35:675-698.
29. Milgram NW, Head E, Weiner E, Thomas E. Cognitive functions and aging in the dog: Acquisition of nonspatial visual tasks. Behav Neurosci 1994;108:57-68.
30. Chan AD, Nippak PM, Murphey H, et al. Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. Behav Neurosci 2002; 116:443-454.
31. Engel RR, Satzger W, Gunther W, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992;2: 149-155.
32. Lombardi GF. Pharmacological treatment with phosphatidylserine of 40 ambulatory patients with senile dementia syndrome. Minerva Med 1989;80:599-602.
33. Siwak CT, Tapp PD, Milgram NW. Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem 2001;8:65-70.
34. Siwak CT, Tapp PD, Zicker SC, et al. Locomotor activity rhythms in dogs with age and cognitive status. Behav Neurosci 2003; 117: 813-824.
35. Dodd CE, Zicker SC, Jewell DE, Fritsch DA, Lowry SR, Allen TA. Can a fortified food affect the behavioral manifestations of age-related cognitive decline in dogs? Vet Med 2003;98:396-408.
36. Studzinski CM, Araujo JA, Milgram NW. The canine model of human cognitive aging and dementia: Pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuropharmacol Biol Psychiatry 2005;29:489-498.
37. Tasakiris S, Deconstantinos G. Phosphatidylserine and calmodulin effects on Ca2+-stimulated ATPase and acetylcholinesterase activities in the dog brain synatosomal plasma membranes. Int J Biochem 1985; 17:1117-1119.
38. Re G, Miolo A, Badino P. Phosphatidylserine for brain aging in dogs and cats: a pharmacological glance. Proc 9th Eur Soc Vet Clin Ethology Meet 2003:53-57.
39. Yamatoya H, Sakai M, Kudo S. The effects of soybean transphosphatidylated phosphatidylserine on cholinergic synaptic functions of mice. Jpn J Pharmacol 2000;84:93-96.
40. Gelbmann CM, Muller WE. Chronic treatment with phosphatidylserine restores muscarinic cholinergic receptor deficits in the aged mouse brain. Neurobiol Aging 1992;13:45-50.
41. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003;60:1779-1792.
42. Chopin P, Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galantamine on scopolamine-induced amnesia in rats. Psychopharmacology 1992;106:26-30.
43. Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HTIA receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol 1994;46:316-318.
44. Huguet F, Tarrade T. Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba extract. J Pharm Pharmacol 1992;44:24-27.
45. Lee TF, Chen CF, Wang LC. Effect of ginkgolides on beta-amyloid- suppressed acetylcholine release from rat hippocampal slices. Phytother Res 2004;18:556-560.
46. Nathan P. Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology? Med Hypotheses 2000;55:491-493.
47. Taylor JE. Binding of neuromediators to their receptors in rat brain. Effect of chronic administration of Ginkgo biloba extract. Presse Med 1986;15:1491-1493.
48. Wang Y, Wang L, Wa J, Cai C. The in vivo synaptic plasticity mechanism of EGb 761-induced enhancement of spatial learning and memory in aged rats. Br J Pharmacol 2006;148:147-153.
49. Williams B, Watanabe CM, Schultz PG, Krucker T. Age-related effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging 2004;25:955-962.
50. Bastianetto S, Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol Aging 2002;23:891-889.
51. Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000;49:427-435.
52. Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. J Nutr Biochem 2004;15:749-756.
53. Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 2001;889:181-190.
54. Dakshinamurti K, Paulose CS, Siow YL. Neurobiology of pyridoxine. In: Reynolds RD, Leklem JE eds. Vitamin B6: Its Role in Health and Disease. New York: Alan R Liss, 1995:99-121.
55. Behl C, Moosmann B. Antioxidant neuroprorection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002;33:182-191.
56. Rofina JE, van Ederen AM, Toussaint MJ, et al. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res 2006;1069:216-226.
57. Skoumalova A, Rofina J, Schwippelova Z, Gruys E, Wilhelm J. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 2003;38:711-719.
58. Crook TH, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992;28:61-66.
59. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in age associated memory impairment. Neurology 1991;41:644-649.
60. Cenacchi B, Bertoldin T, Farina C, Fiori MG, Crepaldia G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging 1993;5: 123-133.
61. Furushiro M, Suzuki S, Shishido Y, et al. Effects of oral administration of soybean lecithin transphosphatidylated phosphatidylserine on impaired learning of passive avoidance in mice. Jpn J Pharmacol 1997; 75:447-450.
62. Kataoka-Kato A, Ukai M, Sakai M, Kudo S, Kameyama T. Enhanced learning of normal adult rodents by repeated oral administration of soybean transphosphatidylated phosphatidylserine. J Pharmacol Sci 2005;98:307-314.
63. Suzuki S, Yamatoya H, Sakai M, Kataoka A, Furishiro M, Kudo S. Oral administration of soybean lecithin transphophatidylate phosphatidylserine improves memory impairment in aged rats. J Nutr 2001;131: 2951-2956.
64. Hoffman JR, Donato A, Robbins SJ. Ginkgo biloba promotes short-term retention of spatial memory in rats. Pharmacol Biochem Behav 2004;77:533-539.
65. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des 2004;10:261-264.
66. Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba Egb761 in Alzheimer's disease. Neuropsychobiol 2002;45:19-26.
67. Wang SJ, Chen HH. Ginkgolide B, a constituent of Ginkgo biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminals. Eur J Pharmacol 2005;514:141-149.
68. Ikeda-Douglas CJ, Zicker SC, Estrada J, Jewell DE, Zicker NW. Prior experience, antioxidants, and mitochondrial cofactors improve cognitive function in aged beagles. Vet Ther 2004;5:5-16.
69. Head E, Thomton PI, Tong L, Cotman CW. Initiation and propagation of molecular cascades in human brain aging: Insight from the canine model to promote successful aging. J Neurochem 2000;82:375-381.